-
公开(公告)号：US20170226192A1
公开(公告)日：2017-08-10
申请号：US15120246
申请日：2015-02-19
Applicant: Jody BERRY , Erica SAPHIRE
Inventor： Jody BERRY , Erica SAPHIRE
IPC: C07K16/10 , G01N33/569
CPC classification number: C07K16/10 , A61K39/08 , A61K39/12 , A61K39/42 , A61K2039/505 , A61K2039/575 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/624 , C07K2317/76 , C12N7/00 , C12N2760/14122 , C12N2760/14134 , C12N2760/14222 , C12N2760/14234 , G01N33/56983 , G01N2333/08 , G01N2469/10
Abstract: The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to a filovirus (e.g., Marburg virus (MARV)), including antibodies that cross-react with at least two filoviruses. Such antibodies are useful for the prevention and treatment of filovirus infection. The invention also provides pharmaceutical compositions comprising the MARV-binding antibodies, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
-
公开(公告)号：US20140286960A1
公开(公告)日：2014-09-25
申请号：US14235315
申请日：2012-07-27
Applicant: Jody Berry , Laura Saward , Robyn Cassan , Xiaobing Han , Mohammad Javad Aman , Rajan P. Adhikari , Hatice Karauzum
Inventor： Jody Berry , Laura Saward , Robyn Cassan , Xiaobing Han , Mohammad Javad Aman , Rajan P. Adhikari , Hatice Karauzum
CPC classification number: A61K39/40 , A61K45/06 , A61K2039/505 , A61K2039/507 , C07K16/1271 , C07K16/1275 , C07K2317/30 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for the treatment or prevention of Staphyloccus aureus infection in a subject are provided. Antibody compositions comprising monoclonal antibodies to alpha-hemolysin protein are also provided. The methods provide administering a composition to the subject in an amount effective to reduce or eliminate or prevent relapse S. aureus bacterial infection and/or induce an immune response to Staphylococcus aureus alpha-hemolysin.
Abstract translation: 提供用于治疗或预防受试者中金黄色葡萄球菌感染的组合物和方法。 还提供了包含对α-溶血素蛋白的单克隆抗体的抗体组合物。 所述方法提供以有效减少或消除或预防金黄色葡萄球菌细菌感染和/或诱导对金黄色葡萄球菌α-溶血素的免疫应答的量向受试者施用组合物。
-
公开(公告)号：US20140127215A1
公开(公告)日：2014-05-08
申请号：US13976530
申请日：2011-12-29
Applicant: Jody Berry , Darrell Johnstone , Bonnie Tighe , Marianela Lopez , Joyee George , Xiaobing Han
Inventor： Jody Berry , Darrell Johnstone , Bonnie Tighe , Marianela Lopez , Joyee George , Xiaobing Han
CPC classification number: A61K39/40 , A61K39/08 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/1282 , C07K16/40 , C07K2317/76
Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a vertebrate subject are provided. The methods provide administering a composition to the vertebrate subject in an amount effective to reduce or eliminate or prevent relapse of Clostridium difficile bacterial infection and/or induce an immune response to the protein. Methods for the treatment or prevention of Clostridium difficile infection in a vertebrate are also provided.
Abstract translation: 提供了用于治疗或预防脊椎动物难辨梭状芽胞杆菌感染的组合物和方法。 所述方法提供以有效减少或消除艰难梭菌细菌感染复发和/或诱导对蛋白质的免疫应答的量向脊椎动物受试者施用组合物。 还提供了用于治疗或预防脊椎动物艰难梭菌感染的方法。
-
公开(公告)号：US20080081047A1
公开(公告)日：2008-04-03
申请号：US10581613
申请日：2004-12-06
Applicant: Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
Inventor： Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
CPC classification number: C07K16/10 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/76 , G01N33/56983
Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterisation of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
Abstract translation: 迫切需要识别SARS冠状病毒（SARS-HCoV）的单克隆抗体试剂。 在本报告中，我们根据其特异性，结合要求和生物活性，描述mAb对SARS-HCoV的发展和免疫化学表征。 通过ELISA进行初步筛选，使用高度纯化的病毒作为包被抗原，导致17个mAb的选择。 5个mAb显示出与变性穗蛋白的Western免疫印迹反应性，其中两个显示出在体外中和SARS-HCoV的能力。 另外四种Western免疫印迹阴性mAb也中和了病毒。 这些抗体可用于诊断测试，致病性和疫苗研究的开发。
-
公开(公告)号：US09505847B2
公开(公告)日：2016-11-29
申请号：US13592286
申请日：2012-08-22
Applicant: Robyn Cassan , Jody Berry , Darrell Johnstone , Derek Toth , Joyee Antony George , Bonnie Tighe
Inventor： Robyn Cassan , Jody Berry , Darrell Johnstone , Derek Toth , Joyee Antony George , Bonnie Tighe
CPC classification number: C07K16/1282 , A61K39/40 , A61K45/06 , A61K2039/505 , C07K16/40 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
Abstract translation: 提供了用于治疗或预防受试者艰难梭菌感染的组合物和方法。 组合物包含对艰难梭菌毒素A的抗体。所述方法提供以有效减少或消除或预防艰难梭菌细菌感染复发的量向对象施用抗体。
-
Patent Agency Ranking
公开(公告)号：US20140004118A1
公开(公告)日：2014-01-02
申请号：US13592286
申请日：2012-08-22
Applicant: Robyn Cassan , Jody Berry , Darrell Johnstone , Derek Toth
Inventor： Robyn Cassan , Jody Berry , Darrell Johnstone , Derek Toth
CPC classification number: C07K16/1282 , A61K39/40 , A61K45/06 , A61K2039/505 , C07K16/40 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for the treatment or prevention of Clostridium difficile infection in a subject are provided. The compositions comprise antibodies to Clostridium difficile toxin A. The methods provide for administering the antibodies to a subject in an amount effective to reduce or eliminate or prevent relapse from Clostridium difficile bacterial infection.
Abstract translation: 提供了用于治疗或预防受试者艰难梭菌感染的组合物和方法。 组合物包含对艰难梭菌毒素A的抗体。所述方法提供以有效减少或消除或预防艰难梭菌细菌感染复发的量向对象施用抗体。
-
公开(公告)号：US07622112B2
公开(公告)日：2009-11-24
申请号：US10581613
申请日：2004-12-06
Applicant: Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
Inventor： Jody Berry , Steven Jones , Xin Yong Yuan , Mike Gubbins , Anton Andonov , Hana Weingartl , Mike Drebot , Frank Plummer
CPC classification number: C07K16/10 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/76 , G01N33/56983
Abstract: Monoclonal antibody reagents that recognize the SARS-coronavirus (SARS-HCoV) are needed urgently. In this report we describe the development and immunochemical characterization of mAbs against the SARS-HCoV based upon their specificity, binding requirements, and biological activity. Initial screening by ELISA, using highly purified virus as the coating antigen, resulted in the selection of seventeen mAbs. Five mAbs exhibited Western immunoblot reactivity with the denatured spike protein, of which two demonstrated the ability to neutralize SARS-HCoV in vitro. Another four Western immunoblot-negative mAbs also neutralize the virus. These antibodies will be useful for the development of diagnostic tests, pathogenicity and vaccine studies.
Abstract translation: 迫切需要识别SARS冠状病毒（SARS-HCoV）的单克隆抗体试剂。 在本报告中，我们根据其特异性，结合要求和生物活性，描述mAb对SARS-HCoV的发展和免疫化学表征。 通过ELISA进行初步筛选，使用高度纯化的病毒作为包被抗原，导致17个mAb的选择。 5个mAb显示出与变性穗蛋白的Western免疫印迹反应性，其中两个显示出在体外中和SARS-HCoV的能力。 另外四种Western免疫印迹阴性mAb也中和了病毒。 这些抗体可用于诊断测试，致病性和疫苗研究的开发。
-
公开(公告)号：US20170183396A1
公开(公告)日：2017-06-29
申请号：US15120245
申请日：2015-02-19
Applicant: Jody BERRY , Grant MCCLARTY , Kelly WARFIELD , Mohammad Javad AMAN
Inventor： Jody BERRY , Grant MCCLARTY , Kelly WARFIELD , Mohammad Javad AMAN
IPC: C07K16/10 , G01N33/569
CPC classification number: C07K16/10 , A61K2039/505 , C07K2317/34 , C07K2317/56 , C07K2317/76 , G01N33/56983 , G01N2333/08
Abstract: The present disclosure provides antibodies, and antigen-binding fragments thereof that bind to EBOV glycoprotein. The present disclosure further provides hybridoma cell lines and methods for making and using the compositions provided herein.
-
公开(公告)号：US08753635B2
公开(公告)日：2014-06-17
申请号：US12301034
申请日：2007-05-17
Applicant: Raymond Tsang , Jody Berry , Xin Yuan , Cindi Corbett , Mike Gubbins , Amin Kabani , Lisa Schmidt
Inventor： Raymond Tsang , Jody Berry , Xin Yuan , Cindi Corbett , Mike Gubbins , Amin Kabani , Lisa Schmidt
IPC: A61K39/40 , A61K39/395 , A61K39/00 , A61K39/07
CPC classification number: C07K16/1278 , A61K35/74 , A61K38/00 , A61K39/39 , A61K2039/505 , C07K14/32 , C07K16/1275 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a Bacillus anthracis infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against Bacillus anthracis infection.
Abstract translation: 描述了还具有中和活性的F20G75，F20G76和F20G77的抗PA单克隆抗体的表征和分离。 单克隆抗体可以用作用于治疗疑似患有或具有或具有炭疽芽孢杆菌感染的风险的个体的药物组合物。 单克隆抗体结合包含PA，ASFFDI的氨基酸311-316，或包含PA，SEVHGNAEVHASFFDIGSSVSAGFSNSNSS的氨基酸301-330的较大片段的特定区域。 可以使用包含这些肽的疫苗来免疫针对炭疽芽孢杆菌感染的个体。
-
公开(公告)号：US20100003263A1
公开(公告)日：2010-01-07
申请号：US12301034
申请日：2007-05-17
Applicant: Raymond Tsang , Jody Berry , Xin Yuan , Cindi Corbett , Mike Gubbins , Amin Kabani , Lisa Schmidt
Inventor： Raymond Tsang , Jody Berry , Xin Yuan , Cindi Corbett , Mike Gubbins , Amin Kabani , Lisa Schmidt
IPC: A61K39/395 , C07K16/12 , C07K7/06 , A61P39/00
CPC classification number: C07K16/1278 , A61K35/74 , A61K38/00 , A61K39/39 , A61K2039/505 , C07K14/32 , C07K16/1275 , C07K2317/24 , C07K2317/76 , C07K2317/92
Abstract: The characterization and isolation of F20G75, F20G76 and F20G77, anti-PA monoclonal antibodies which also have neutralizing activities is described. The monoclonal antibodies may be used as a pharmaceutical composition for treating individuals suspected of or at risk of or having a Bacillus anthracis infection. The monoclonal antibodies bind to a specific region comprising amino acids 311-316 of PA, ASFFDI or a larger fragment comprising amino acids 301-330 of PA, SEVHGNAEVHASFFDIGSSVSAGFSNSNSS. Vaccines comprising these peptides may be used to immunize individuals against Bacillus anthracis infection.
Abstract translation: 描述了还具有中和活性的F20G75，F20G76和F20G77的抗PA单克隆抗体的表征和分离。 单克隆抗体可以用作用于治疗疑似患有或具有或具有炭疽芽孢杆菌感染的风险的个体的药物组合物。 单克隆抗体结合包含PA，ASFFDI的氨基酸311-316，或包含PA，SEVHGNAEVHASFFDIGSSVSAGFSNSNSS的氨基酸301-330的较大片段的特定区域。 可以使用包含这些肽的疫苗来免疫针对炭疽芽孢杆菌感染的个体。
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.023 seconds)
